In prostate cancer, ERβ exerts anti-tumor effects by upregulating pro-apoptotic genes such as p53 upregulated modulator of apoptosis (PUMA), and by inhibiting the hypoxia-inducible factor 1-alpha (HIF-1α) pathway [38,39]. Here, ESR2 is linked to prostate carcinoma.